Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

ADR Update: Next up, LGS

Data from two Phase III trials (with 171 and 225 patients, respectively) of Epidiolex in Lennox-Gastaut (LGS) patients are coming soon with the first trial to report out in June with the second coming in Q316. In the latest expanded access program data, Epidiolex reduced atonic/drop seizure frequency by a median of 71.1%. Previous data suggest a placebo response rate in LGS of around 10% which, combined with the size of the trials, indicates sufficient power to demonstrate a difference.

Update: Next up, LGS

Data from two Phase III trials (with 171 and 225 patients, respectively) of Epidiolex in Lennox-Gastaut (LGS) patients are coming soon with the first trial to report out in June with the second coming in Q316. In the latest expanded access programme data, Epidiolex reduced atonic/drop seizure frequency by a median of 71.1%. Previous data suggest a placebo response rate in LGS of around 10% which, combined with the size of the trials, indicates sufficient power to demonstrate a difference.

ADR Outlook: A transformative year

With four Phase III trials of Epidiolex (cannabidiol, or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line readouts in 2016 (three in H116), investors are understandably laser focused on these programs. Based on an analysis of the previous results of other molecules in Dravet and LGS, as well as data from the expanded access program, we are confident the trials are sufficiently powered to demonstrate a stat...

Outlook: 2016: A transformative year

With four Phase III trials of Epidiolex (cannabidiol or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line readouts in 2016 (with three in H116), investors are understandably laser-focused on these programmes. Based on an analysis of the previous results of other molecules in Dravet and LGS, as well as data from the expanded access programme, we are confident that the trials are sufficiently powered to demon...

Institutional Comment: Daily comment

ADR Update: Entering pivotal territory

GW has initiated its first Phase III pivotal study for Epidiolex in Dravet syndrome, a highly debilitating and treatment refractory form of childhood epilepsy. This is the first of four planned Phase III trials with Epidiolex (one more in Dravet, two in Lennox-Gastaut syndrome), all due to begin in Q215. Epidiolex is a major valuation driver, so top-line data by end-2015 from the first Phase III now underway is a significant catalyst. We also look forward to further physician-led data to be pres...

Update: Entering pivotal territory

GW has initiated its first Phase III pivotal study for Epidiolex in Dravet syndrome, a highly debilitating and treatment refractory form of childhood epilepsy. This is the first of four planned Phase III trials with Epidiolex (one more in Dravet, two in Lennox-Gastaut syndrome), all due to begin in Q215. Epidiolex is a major valuation driver, so top-line data by end-2015 from the first Phase III now underway is a significant catalyst. We also look forward to further physician-led data to be pres...

Institutional Comment: Daily comment

ADR Outlook: High hopes for cannabinoids

The expansion of GW Pharmaceuticals’ (GW's) cannabinoid portfolio beyond Sativex continues to gather momentum. At the forefront is Epidiolex, poised to enter an extensive Phase III clinical program for two refractory childhood epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome. With results from one of these studies now due by end-2015, the clinical development timeline of Epidiolex has exceeded our expectations, while also moving ahead of potential competition. Our DCF now stands at $1.7...

Outlook: High hopes for cannabinoids

The expansion of GW Pharmaceuticals’ (GW's) cannabinoid portfolio beyond Sativex continues to gather momentum. At the forefront is Epidiolex, poised to enter an extensive Phase III clinical programme for two refractory childhood epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome. With results from one of these studies now due by end-2015, the clinical development timeline of Epidiolex has exceeded our expectations, while also moving ahead of potential competition. Our DCF now stands at £...

Institutional Comment: Daily comment